Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Atosiban→

Atosiban Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
90779-69-4
Molecular formula
C43H67N11O12S2
Molecular weight
994.2 g/mol
Drug class
Oxytocin-receptor antagonisttocolytic peptide
Mechanism of action
Competitively antagonises oxytocin at its receptor and also binds vasopressin receptors; this reduces uterine contraction frequency and tone.
Indications / reported uses
  • Delay of imminent pre-term birth in selected pregnant adult women meeting the product-specific clinical criteria

Sources: UK SmPC (eMC)

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Atosiban Environmental Risk Assessment (ERA) (the Atosiban ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.